Twelve Points Wealth Management LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Twelve Points Wealth Management LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,616 shares of the biopharmaceutical company's stock, valued at approximately $611,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after buying an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP lifted its position in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock worth $193,274,000 after purchasing an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC raised its stake in shares of Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GILD shares. Bank of America reiterated a "buy" rating and issued a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an "outperform" rating and a $110.00 price objective for the company. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

GILD traded up $1.63 on Wednesday, hitting $95.48. 3,188,643 shares of the company's stock traded hands, compared to its average volume of 6,654,445. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $118.99 billion, a price-to-earnings ratio of 1,061.06, a P/E/G ratio of 1.31 and a beta of 0.18. The company's 50 day simple moving average is $92.00 and its 200-day simple moving average is $85.44.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.29 earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.